| GENERIC NAME | PreMixed Insulin Inj. |
| MARKETING |
Co. markets the following premixed insulins: MixtardŽ 10 (Short A.: 10%; Intermediate A.: 90%) MixtardŽ 20 MixtardŽ 30 MixtardŽ 40 MixtardŽ 50 |
| DESCRIPTION |
A. Mixt.: - Short Acting Insulin (Soluble Insulin) - Intermediate Acting Insulin Suspension [Isophane (NPH) Insulin] |
| INDICATION'S | Diabetes |
| OBSERVATION'S | In some countries Co. s premixed insulin is marketed as NovolinŽ. In the USA only NovolinŽ 70/30 is available |
| SALES VALUE |
- 2001: US$ 1.83 Billion - 2004: US$ 2.40 Billion |
| STATUS | US Patent Expiration Date: 09.28.2013 |
| COMPANY | This data is not available for free |
| PATENT NUMBER | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |